Abstract
Background: Inappropriate arginine vasopressin (AVP) secretion has been reported in schizophrenic patients. However, there is lack of information on serum level of copeptin and its diagnostic performance in schizophrenia. This study therefore, evaluated serum copeptin and its diagnostic performance in schizophrenic patients.
Methods: Sixty subjects (30.02 ± 7.17 years) with schizophrenia (19 drug naïve [DNS] and 41 schizophrenics on treatment [SOT]) and 30 healthy individuals (33.62 ± 9.05 years) with no history of schizophrenia were enrolled into this study. Schizophrenia was diagnosed using the Tenth edition of the International Classification of Diseases and Related Health Problems (ICD-10). Estimation of serum copeptin, plasma electrolytes (potassium, sodium and chloride) and uric acid was done using ELISA, Ion-Selective electrode (ISE) and enzymatic method respectively.
Results: Copeptin was significantly higher while uric acid, potassium and sodium levels were significantly lower in patients with schizophrenia compared with controls. Similarly, copeptin was significantly higher while sodium, potassium and uric acid levels were significantly lower in DNS and SOT compared with controls. However, insignificant elevation in copeptin level and insignificant
reduction in sodium, potassium, chloride and uric acid levels were observed in DNS compared with SOT. The Area under the curve (AUROC) for copeptin was 0.686 (P= 0.004).
Conclusion: There is elevated copeptin level in patients with schizophrenia and that copeptin levels might be a valuable tool in the diagnosis of schizophrenia.
Keywords: Arginine vasopressin, Copeptin, Diagnostic performance, ICD-10, Schizophrenia.
Résumé
Introduction: La sécrétion inappropriée d’arginine vasopressine (AVP) a été reportée dans des patients schizophréniques. Cependant, il y a manque d’information sur le niveau du sérum copeptin et sa performance diagnostique dans la schizophrénie. Cette étude alors, évaluait le sérum copeptin et sa performance diagnostique dans les patients schizophrénique.
Méthodes: Soixante sujets (30,02 7,17 ans) avec la schizophrénie (19 médicaments naïve [DNS] et 41 schizophréniques sur traitement [SOT] et 30 individus sains (33,62 9,05 ans) sans histoire de schizophrénie étaient enrôlés dans cette étude. La schizophrénie était diagnostiquée utilisant la dixième édition de la classification internationale des maladies et problèmes reliés à la santé (ICD-10). L’estimation du sérum Copeptine, plasma électrolytes (potassium, sodium et chlore) et acide urique était fait en utilisant ELIZA, l’ion-électrode sélective (ISE) et la méthode enzymatique respectivement.
Résultats: La copeptine était de manière significative plus haute tandis que le niveau de l’acide urique, potassium et sodium étaient de manière significative basse dans les patients avec la schizophrénie comparé avec les contrôles. De même, la copeptine était de manière significative haute tandis que le niveau du sodium, potassium et l’acide urique étaient de manière significative basse dans le DNS comparé avec le SOT. Cependant, élévation non significative le niveau de copeptine et réduction non significative dans les niveaux de sodium, potassium, chlore et acide urique étaient observés dans le DNS comparé avec le SOT. La surface sous la courbe (AUROC) pour copeptine était 0,686 (p0,004).
Conclusion : Il y a un niveau élevé de copeptine dans les patients avec la schizophrénie et que les niveaux de copeptine pourraient être une mesure de valeur dans le diagnostique de la schizophrénie.
Mots clé: Arginine vasopressine, Copeptine, Performance Diagnostique, ICD-10, Schizophrénie.
Correspondence: Dr. K.S. Akinlade, Metabolic Research Unit, Department of Chemical Pathology, College of Medicine, University of Ibadan, Ibadan, Nigeria. E-mail: ksakinlade@yahoo.co.uk
Literaturhinweise
Bhugra D. The Global Prevalence of Schizophrenia. PLoS Med 2005; 2(5): e151.
Bahn S, Guest P, Harris L, Levin Y, and Krishnamurthy D. Biomarkers for schizophrenia. Patent no: WO 2011121361 A1. Filing date Mar 31, 2011, Publication date Oct 6, 2011.
Smith M and Segal J. Schizophrenia: Signs, Types and Causes. http://www.helpguide.org/mental/ schizophrenia_symptom.htm (accessed on 12th June, 2014).
Saha S, Chant D, Welham J and McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
Weickert CS, Weickert TW, Pillai A and Buckley PF. Biomarkers in Schizophrenia: A brief conceptual consideration. Disease Markers 2013; 35 (1): 3 - 9.
Putmam FW. Diagnosis and Treatment of Multiple Personality Disorder. New York: The Guilford Press. 1989; pp. 351. ISBN 0-898662-177-1.
Hayes JA and Mitchell JC. Mental health professionals’ skepticism about multiple personality disorder. Professional Psychology: Research and Practice 1994; 25(4), 410-415.
Morgenthaler NG, Struck J, Alonso C and Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119.
Katan M and Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Eur J Med Services 2010; 140: 13101.
Muller B, Morgenthaler N, Stolz D, et al. 2007. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37(2): 145-152.
Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131(4): 1058 - 1067.
Limper M, Goeijenbier M, Wagenaar JF, et al. Copeptin as a predictor of disease severity and survival in leptospirosis. J Infect 2010; 61(1):92-94.
Katan M, Nigro N, Fluri F, et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology 2011; 76(6) 563- 566.
Dong XQ, Huang M, Yang SB, et al. Copeptin is associated with mortality in patients with traumatic brain injury. J Trauma 2011; 71(5): 1194 -1198.
Nickel CH, Bingisser R and Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Medicine 2012; 10: 17.
Khan SQ, Dhillon OS, O’Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007; 115(16):2103-2110.
Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009; 30(10):1187-1194.
Alehagen U, Dahlström U, Rehfeld JF and Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA 2011; 305(20):2088-2095.
Goldman MB, Robertson GL, Luchins DJ, et al. Psychotic exacerbations and enhanced vasopressin secretion in schizophrenic patients with hyponatremia and polydipsia. Arch Gen Psychiatry 1997; 54(5):443-449.
Ohsawa H, Kishimoto T, Shimayoshi N, et al. Atrial natriuretic peptide and arginine vasopressin secretion in schizophrenic patients. Acta Psychiatr Scand 1993; 88(2):130-134.
Kawai N, Baba A, Suzuki T and Shiraishi H. Roles of arginine vasopressin and atrial natriuretic peptide in polydipsia-hyponatremia of schizophrenic patients. Psychiatry Res 2001; 101(1):39-45.
Ryan MC, Sharifi N, Condren R and Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 2004; 29(8):1065–1070.
Ackland J, Ratter S, Bourne G and Rees LH. Pro-opiomelanocortin peptides in the human fetal pituitary. Regul Pept 1983; 6: 51 – 61.
Walsh P, Spelman L, Sharifi N and Thakore JH. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 2005; 30: 431 – 437.
Bhatia MS, Balkrishna, Dhar NK, Khurana SK and Bohra N. Schizophrenia-Electrolyte profile and the effect of treatment. Indian Journal of Psychiatry 1987; 29(3): 275-277.
Land H, Schutz G, Schmale H and Richter D. Nucleotides sequence of cloned DNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature 1982; 295:299-303.
Vaiva G, Thomas P, Leroux JM, et al. Erythrocyte superoxide dismutase (eSOD) determination in positive moments of psychosis. Therapie 1994; 49(4):343-348.
Yao JK, Reddy R and van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 1998; 80(1):29-39.
Surapaneni DK, Adapa SR, Preeti K, et al. Shilajit attenuates behavioural symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats. J Ethnopharmacol 2012; 143(1): 91-99.